SEC Form 4 · accession 0001209191-17-045075
GENOMIC HEALTH INC · GHDX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
G Bradley Cole
Officer — COO
Period of report
Jul 11, 2017
Accepted (ET)
Jul 13, 2017 · 5:23 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001131324
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jul 11, 2017 | M | 4,927 | $17.33 | A | 44,862 | D | |
| Common StockF1 | Jul 11, 2017 | M | 73 | $17.33 | A | 44,935 | D | |
| Common StockF2,F3,F4,F1 | Jul 11, 2017 | S | 4,927 | $32.5245 | D | 40,008 | D | |
| Common StockF2,F3,F5,F1 | Jul 11, 2017 | S | 73 | $33.13 | D | 39,935 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F6 | $17.33 | Jul 11, 2017 | M | 4,927 | D | — | Dec 4, 2018 | Common Stock | 0 | 40,073 | D |
| Employee Stock Option (right to buy)F6 | $17.33 | Jul 11, 2017 | M | 73 | D | — | Dec 4, 2018 | Common Stock | 0 | 40,000 | D |
Explanation of responses
- F1Includes an aggregate of 18,174 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.
- F2These sales of common stock were effected pursuant to Rule 10b5-1 sales plan adopted by the reporting person on March 9, 2017.
- F3Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within the range indicated.
- F4Represents weighted average sale price. Actual sale prices ranged from $32.12 to $33.03.
- F5Represents actual sale price.
- F6The option became exercisable as to 25% of the shares on December 4, 2009, and became exercisable as to 1/48th of the shares each full month thereafter.